Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 2396 entries
Sorted by: Best Match Show Resources per page
The gynecologic oncology fellowship interview process: Challenges and potential areas for improvement.

Gynecologic oncology reports

Gressel GM, Van Arsdale A, Dioun SM, Goldberg GL, Nevadunsky NS.
PMID: 28443321
Gynecol Oncol Rep. 2017 Apr 07;20:115-120. doi: 10.1016/j.gore.2017.04.003. eCollection 2017 May.

The application and interview process for gynecologic oncology fellowship is highly competitive, time-consuming and expensive for applicants. We conducted a survey of successfully matched gynecologic oncology fellowship applicants to assess problems associated with the interview process and identify areas...

Cite
Gressel GM, Van Arsdale A, Dioun SM, et al. The gynecologic oncology fellowship interview process: Challenges and potential areas for improvement. Gynecol Oncol Rep. 2017;20:115-120doi: 10.1016/j.gore.2017.04.003.
Gressel, G. M., Van Arsdale, A., Dioun, S. M., Goldberg, G. L., & Nevadunsky, N. S. (2017). The gynecologic oncology fellowship interview process: Challenges and potential areas for improvement. Gynecologic oncology reports, 20115-120. https://doi.org/10.1016/j.gore.2017.04.003
Gressel, Gregory M, et al. "The gynecologic oncology fellowship interview process: Challenges and potential areas for improvement." Gynecologic oncology reports vol. 20 (2017): 115-120. doi: https://doi.org/10.1016/j.gore.2017.04.003
Gressel GM, Van Arsdale A, Dioun SM, Goldberg GL, Nevadunsky NS. The gynecologic oncology fellowship interview process: Challenges and potential areas for improvement. Gynecol Oncol Rep. 2017 Apr 07;20:115-120. doi: 10.1016/j.gore.2017.04.003. eCollection 2017 May. PMID: 28443321; PMCID: PMC5393158.
Copy Download .nbib Format: NLM
Cortactin promotes cell migration and invasion through upregulation of the dedicator of cytokinesis 1 expression in human colorectal cancer.

Oncology reports

Jing X, Wu H, Ji X, Wu H, Shi M, Zhao R.
PMID: 27633051
Oncol Rep. 2016 Oct;36(4):1946-1952. doi: 10.3892/or.2016.5058. Epub 2016 Aug 31.

Cortactin (CTTN), a major substrate of the Src tyrosine kinase, has been implicated in cell proliferation, motility and invasion in various types of cancer. However, the molecular mechanisms of CTTN-driven malignant behavior remain unclear. In the current study, we...

Cite
Jing X, Wu H, Ji X, et al. Cortactin promotes cell migration and invasion through upregulation of the dedicator of cytokinesis 1 expression in human colorectal cancer. Oncol Rep. 2016;36(4):1946-1952doi: 10.3892/or.2016.5058.
Jing, X., Wu, H., Ji, X., Wu, H., Shi, M., & Zhao, R. (2016). Cortactin promotes cell migration and invasion through upregulation of the dedicator of cytokinesis 1 expression in human colorectal cancer. Oncology reports, 36(4), 1946-1952. https://doi.org/10.3892/or.2016.5058
Jing, Xiaoqian, et al. "Cortactin promotes cell migration and invasion through upregulation of the dedicator of cytokinesis 1 expression in human colorectal cancer." Oncology reports vol. 36,4 (2016): 1946-1952. doi: https://doi.org/10.3892/or.2016.5058
Jing X, Wu H, Ji X, Wu H, Shi M, Zhao R. Cortactin promotes cell migration and invasion through upregulation of the dedicator of cytokinesis 1 expression in human colorectal cancer. Oncol Rep. 2016 Oct;36(4):1946-1952. doi: 10.3892/or.2016.5058. Epub 2016 Aug 31. PMID: 27633051.
Copy Download .nbib Format: NLM
Endometrioid adenocarcinoma associated with endometrial stromal sarcoma: A rare, often unrecognized collision tumor.

Gynecologic oncology reports

Kim G, Pham HQ, Ramzan A, Elishaev E, Mhawech-Fauceglia P.
PMID: 26425710
Gynecol Oncol Rep. 2015 May 01;13:8-12. doi: 10.1016/j.gore.2015.04.005. eCollection 2015 Aug.

We are reporting 3 cases of the uterine corpus with collision of endometrioid adenocarcinoma (EAC) with endometrial stromal sarcoma (ESS). The patients' ages ranged from 36 to 59 years old. The major clinical presentation was abnormal uterine bleeding. Microscopically,...

Cite
Kim G, Pham HQ, Ramzan A, et al. Endometrioid adenocarcinoma associated with endometrial stromal sarcoma: A rare, often unrecognized collision tumor. Gynecol Oncol Rep. 2015;13:8-12doi: 10.1016/j.gore.2015.04.005.
Kim, G., Pham, H. Q., Ramzan, A., Elishaev, E., & Mhawech-Fauceglia, P. (2015). Endometrioid adenocarcinoma associated with endometrial stromal sarcoma: A rare, often unrecognized collision tumor. Gynecologic oncology reports, 138-12. https://doi.org/10.1016/j.gore.2015.04.005
Kim, Grace, et al. "Endometrioid adenocarcinoma associated with endometrial stromal sarcoma: A rare, often unrecognized collision tumor." Gynecologic oncology reports vol. 13 (2015): 8-12. doi: https://doi.org/10.1016/j.gore.2015.04.005
Kim G, Pham HQ, Ramzan A, Elishaev E, Mhawech-Fauceglia P. Endometrioid adenocarcinoma associated with endometrial stromal sarcoma: A rare, often unrecognized collision tumor. Gynecol Oncol Rep. 2015 May 01;13:8-12. doi: 10.1016/j.gore.2015.04.005. eCollection 2015 Aug. PMID: 26425710; PMCID: PMC4563353.
Copy Download .nbib Format: NLM
Ureteroarterial fistula following retrograde ureteral stenting in a patient with a double-barreled wet colostomy for cervical cancer.

Gynecologic oncology reports

Siorek M, Tierney B, Fowler J, Dowell JD.
PMID: 26425720
Gynecol Oncol Rep. 2015 Jun 23;13:44-6. doi: 10.1016/j.gore.2015.06.007. eCollection 2015 Aug.

•Ureteroarterial fistula (UAF) is a rare cause of massive hematuria.•Percutaneous retrograde ureteral stents via DBWC can be done safely in the compliant patient for improved comfort.•Understanding the anatomy, risks, and minimally invasive treatment options for UAF is important for...

Cite
Siorek M, Tierney B, Fowler J, et al. Ureteroarterial fistula following retrograde ureteral stenting in a patient with a double-barreled wet colostomy for cervical cancer. Gynecol Oncol Rep. 2015;13:44-6doi: 10.1016/j.gore.2015.06.007.
Siorek, M., Tierney, B., Fowler, J., & Dowell, J. D. (2015). Ureteroarterial fistula following retrograde ureteral stenting in a patient with a double-barreled wet colostomy for cervical cancer. Gynecologic oncology reports, 1344-6. https://doi.org/10.1016/j.gore.2015.06.007
Siorek, Marek, et al. "Ureteroarterial fistula following retrograde ureteral stenting in a patient with a double-barreled wet colostomy for cervical cancer." Gynecologic oncology reports vol. 13 (2015): 44-6. doi: https://doi.org/10.1016/j.gore.2015.06.007
Siorek M, Tierney B, Fowler J, Dowell JD. Ureteroarterial fistula following retrograde ureteral stenting in a patient with a double-barreled wet colostomy for cervical cancer. Gynecol Oncol Rep. 2015 Jun 23;13:44-6. doi: 10.1016/j.gore.2015.06.007. eCollection 2015 Aug. PMID: 26425720; PMCID: PMC4563588.
Copy Download .nbib Format: NLM
Debulking surgery and hyperthermic intraperitoneal chemotherapy in the management of a recurrent aggressive uterine myxoid leiomyosarcoma with peritoneal dissemination.

Gynecologic oncology reports

Inoue D, Yamamoto M, Sugita G, Kurokawa T, Yoshida Y.
PMID: 26425725
Gynecol Oncol Rep. 2015 Jul 02;13:60-3. doi: 10.1016/j.gore.2015.06.010. eCollection 2015 Aug.

•A rare case of recurrent peritoneal sarcomatosis (PS) arising from aggressive uterine myxoid leiomyosarcoma was described.•Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) has the potential to improve outcomes in PS from uterine sarcoma.•Careful patient selection for cytoreductive surgery with...

Cite
Inoue D, Yamamoto M, Sugita G, et al. Debulking surgery and hyperthermic intraperitoneal chemotherapy in the management of a recurrent aggressive uterine myxoid leiomyosarcoma with peritoneal dissemination. Gynecol Oncol Rep. 2015;13:60-3doi: 10.1016/j.gore.2015.06.010.
Inoue, D., Yamamoto, M., Sugita, G., Kurokawa, T., & Yoshida, Y. (2015). Debulking surgery and hyperthermic intraperitoneal chemotherapy in the management of a recurrent aggressive uterine myxoid leiomyosarcoma with peritoneal dissemination. Gynecologic oncology reports, 1360-3. https://doi.org/10.1016/j.gore.2015.06.010
Inoue, Daisuke, et al. "Debulking surgery and hyperthermic intraperitoneal chemotherapy in the management of a recurrent aggressive uterine myxoid leiomyosarcoma with peritoneal dissemination." Gynecologic oncology reports vol. 13 (2015): 60-3. doi: https://doi.org/10.1016/j.gore.2015.06.010
Inoue D, Yamamoto M, Sugita G, Kurokawa T, Yoshida Y. Debulking surgery and hyperthermic intraperitoneal chemotherapy in the management of a recurrent aggressive uterine myxoid leiomyosarcoma with peritoneal dissemination. Gynecol Oncol Rep. 2015 Jul 02;13:60-3. doi: 10.1016/j.gore.2015.06.010. eCollection 2015 Aug. PMID: 26425725; PMCID: PMC4563799.
Copy Download .nbib Format: NLM
Cervical cancer in low and middle income countries: Addressing barriers to radiotherapy delivery.

Gynecologic oncology reports

LaVigne AW, Triedman SA, Randall TC, Trimble EL, Viswanathan AN.
PMID: 28948205
Gynecol Oncol Rep. 2017 Sep 01;22:16-20. doi: 10.1016/j.gore.2017.08.004. eCollection 2017 Nov.

The global cervical cancer burden falls disproportionately upon women in low and middle-income countries. Insufficient infrastructure, lack of access to preventive HPV vaccines, screening, and treatment, as well as limited trained personnel and training opportunities, continue to impede efforts...

Cite
LaVigne AW, Triedman SA, Randall TC, et al. Cervical cancer in low and middle income countries: Addressing barriers to radiotherapy delivery. Gynecol Oncol Rep. 2017;22:16-20doi: 10.1016/j.gore.2017.08.004.
LaVigne, A. W., Triedman, S. A., Randall, T. C., Trimble, E. L., & Viswanathan, A. N. (2017). Cervical cancer in low and middle income countries: Addressing barriers to radiotherapy delivery. Gynecologic oncology reports, 2216-20. https://doi.org/10.1016/j.gore.2017.08.004
LaVigne, Anna W, et al. "Cervical cancer in low and middle income countries: Addressing barriers to radiotherapy delivery." Gynecologic oncology reports vol. 22 (2017): 16-20. doi: https://doi.org/10.1016/j.gore.2017.08.004
LaVigne AW, Triedman SA, Randall TC, Trimble EL, Viswanathan AN. Cervical cancer in low and middle income countries: Addressing barriers to radiotherapy delivery. Gynecol Oncol Rep. 2017 Sep 01;22:16-20. doi: 10.1016/j.gore.2017.08.004. eCollection 2017 Nov. PMID: 28948205; PMCID: PMC5602511.
Copy Download .nbib Format: NLM
Hormonal based treatment of ovarian anaplastic ependymoma with anastrozole.

Gynecologic oncology reports

Gorski JW, Taylor JS, Zhang J, Liu J, Jazaeri AA.
PMID: 28393092
Gynecol Oncol Rep. 2017 Mar 14;20:93-96. doi: 10.1016/j.gore.2017.03.005. eCollection 2017 May.

OBJECTIVE: Ovarian anaplastic ependymoma is a rare gynecologic malignancy that poses diagnostic and treatment challenges. Treatment of sub-optimally debulked disease usually portends poor prognosis. Molecular testing of tumor specimen can identify more specific targets for additional therapy such as...

Cite
Gorski JW, Taylor JS, Zhang J, et al. Hormonal based treatment of ovarian anaplastic ependymoma with anastrozole. Gynecol Oncol Rep. 2017;20:93-96doi: 10.1016/j.gore.2017.03.005.
Gorski, J. W., Taylor, J. S., Zhang, J., Liu, J., & Jazaeri, A. A. (2017). Hormonal based treatment of ovarian anaplastic ependymoma with anastrozole. Gynecologic oncology reports, 2093-96. https://doi.org/10.1016/j.gore.2017.03.005
Gorski, Justin Wayne, et al. "Hormonal based treatment of ovarian anaplastic ependymoma with anastrozole." Gynecologic oncology reports vol. 20 (2017): 93-96. doi: https://doi.org/10.1016/j.gore.2017.03.005
Gorski JW, Taylor JS, Zhang J, Liu J, Jazaeri AA. Hormonal based treatment of ovarian anaplastic ependymoma with anastrozole. Gynecol Oncol Rep. 2017 Mar 14;20:93-96. doi: 10.1016/j.gore.2017.03.005. eCollection 2017 May. PMID: 28393092; PMCID: PMC5376265.
Copy Download .nbib Format: NLM
Left paraaortic, inframesenteric lymphadenectomy preserving the superior hypogastric plexus supported by indocyanine green (ICG) labeling of the lymphatic compartment in cervical cancer.

Gynecologic oncology reports

Kimmig R, Rusch P, Buderath P, Aktas B.
PMID: 27672677
Gynecol Oncol Rep. 2016 Sep 14;18:14. doi: 10.1016/j.gore.2016.09.002. eCollection 2016 Nov.

Superior hypogastric plexus (SHG) contains mainly sympathetic and most probably also postganglionic parasympathetic fibers. Thus, surgical damage of SHG may cause autonomic pelvic organ dysfunction (Kraima et al., 2015). As already shown for rectal cancer, preservation of the autonomic...

Cite
Kimmig R, Rusch P, Buderath P, et al. Left paraaortic, inframesenteric lymphadenectomy preserving the superior hypogastric plexus supported by indocyanine green (ICG) labeling of the lymphatic compartment in cervical cancer. Gynecol Oncol Rep. 2016;18:14doi: 10.1016/j.gore.2016.09.002.
Kimmig, R., Rusch, P., Buderath, P., & Aktas, B. (2016). Left paraaortic, inframesenteric lymphadenectomy preserving the superior hypogastric plexus supported by indocyanine green (ICG) labeling of the lymphatic compartment in cervical cancer. Gynecologic oncology reports, 1814. https://doi.org/10.1016/j.gore.2016.09.002
Kimmig, Rainer, et al. "Left paraaortic, inframesenteric lymphadenectomy preserving the superior hypogastric plexus supported by indocyanine green (ICG) labeling of the lymphatic compartment in cervical cancer." Gynecologic oncology reports vol. 18 (2016): 14. doi: https://doi.org/10.1016/j.gore.2016.09.002
Kimmig R, Rusch P, Buderath P, Aktas B. Left paraaortic, inframesenteric lymphadenectomy preserving the superior hypogastric plexus supported by indocyanine green (ICG) labeling of the lymphatic compartment in cervical cancer. Gynecol Oncol Rep. 2016 Sep 14;18:14. doi: 10.1016/j.gore.2016.09.002. eCollection 2016 Nov. PMID: 27672677; PMCID: PMC5030370.
Copy Download .nbib Format: NLM
The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: Survey results from members of the society of gynecologic oncologists, a 5-year follow-up.

Gynecologic oncology reports

Huelsmann E, Zighelboim I, Ahmed A, Dewdney S.
PMID: 28317007
Gynecol Oncol Rep. 2017 Feb 16;20:47-50. doi: 10.1016/j.gore.2017.02.005. eCollection 2017 May.

•NACT use among SGO members for ovarian cancer is explored given recent trials.•Fewer SGO members feel they can't predict optimal cytoreduction pre-operatively.•Laparoscopy use has increased both for diagnosis and treatment of ovarian cancer.•Very high optimal cytoreduction rates are reported...

Cite
Huelsmann E, Zighelboim I, Ahmed A, et al. The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: Survey results from members of the society of gynecologic oncologists, a 5-year follow-up. Gynecol Oncol Rep. 2017;20:47-50doi: 10.1016/j.gore.2017.02.005.
Huelsmann, E., Zighelboim, I., Ahmed, A., & Dewdney, S. (2017). The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: Survey results from members of the society of gynecologic oncologists, a 5-year follow-up. Gynecologic oncology reports, 2047-50. https://doi.org/10.1016/j.gore.2017.02.005
Huelsmann, Erica, et al. "The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: Survey results from members of the society of gynecologic oncologists, a 5-year follow-up." Gynecologic oncology reports vol. 20 (2017): 47-50. doi: https://doi.org/10.1016/j.gore.2017.02.005
Huelsmann E, Zighelboim I, Ahmed A, Dewdney S. The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: Survey results from members of the society of gynecologic oncologists, a 5-year follow-up. Gynecol Oncol Rep. 2017 Feb 16;20:47-50. doi: 10.1016/j.gore.2017.02.005. eCollection 2017 May. PMID: 28317007; PMCID: PMC5344220.
Copy Download .nbib Format: NLM
[Corrigendum] Antitumor effects of ZD6474 on head and neck squamous cell carcinoma.

Oncology reports

Sano D, Kawakami M, Fujita K, Kimura M, Yamashita Y, Ishiguro Y, Nishimura G, Matsuda H, Tsukuda M.
PMID: 26781072
Oncol Rep. 2016 Apr;35(4):2495. doi: 10.3892/or.2016.4574. Epub 2016 Jan 18.

Oncol Rep 17: [Related article:] 289–295, 2007; DOI: 10.3892/or.17.2.289 After the publication of the article, the authors noted that the relevance of the findings reported in this article on ZD6474 inhibition of growth of head and neck squamous cell...

Cite
Sano D, Kawakami M, Fujita K, et al. [Corrigendum] Antitumor effects of ZD6474 on head and neck squamous cell carcinoma. Oncol Rep. 2016;35(4):2495doi: 10.3892/or.2016.4574.
Sano, D., Kawakami, M., Fujita, K., Kimura, M., Yamashita, Y., Ishiguro, Y., Nishimura, G., Matsuda, H., & Tsukuda, M. (2016). [Corrigendum] Antitumor effects of ZD6474 on head and neck squamous cell carcinoma. Oncology reports, 35(4), 2495. https://doi.org/10.3892/or.2016.4574
Sano, Daisuke, et al. "[Corrigendum] Antitumor effects of ZD6474 on head and neck squamous cell carcinoma." Oncology reports vol. 35,4 (2016): 2495. doi: https://doi.org/10.3892/or.2016.4574
Sano D, Kawakami M, Fujita K, Kimura M, Yamashita Y, Ishiguro Y, Nishimura G, Matsuda H, Tsukuda M. [Corrigendum] Antitumor effects of ZD6474 on head and neck squamous cell carcinoma. Oncol Rep. 2016 Apr;35(4):2495. doi: 10.3892/or.2016.4574. Epub 2016 Jan 18. PMID: 26781072.
Copy Download .nbib Format: NLM
Erratum to: Update on Management of Cancer-Related Cachexia.

Current oncology reports

Anderson LJ, Albrecht ED, Garcia JM.
PMID: 28293870
Curr Oncol Rep. 2017 Mar;19(3):22. doi: 10.1007/s11912-017-0595-4.

No abstract available.

Cite
Anderson LJ, Albrecht ED, Garcia JM. Erratum to: Update on Management of Cancer-Related Cachexia. Curr Oncol Rep. 2017;19(3):22doi: 10.1007/s11912-017-0595-4.
Anderson, L. J., Albrecht, E. D., & Garcia, J. M. (2017). Erratum to: Update on Management of Cancer-Related Cachexia. Current oncology reports, 19(3), 22. https://doi.org/10.1007/s11912-017-0595-4
Anderson, Lindsey J, et al. "Erratum to: Update on Management of Cancer-Related Cachexia." Current oncology reports vol. 19,3 (2017): 22. doi: https://doi.org/10.1007/s11912-017-0595-4
Anderson LJ, Albrecht ED, Garcia JM. Erratum to: Update on Management of Cancer-Related Cachexia. Curr Oncol Rep. 2017 Mar;19(3):22. doi: 10.1007/s11912-017-0595-4. PMID: 28293870.
Copy Download .nbib Format: NLM
RE: Pattern of and reason for postoperative residual disease in patients with advanced ovarian cancer following upfront radical debulking surgery.

Gynecologic oncology reports

Fagotti A, Vizzielli G, Petrillo M, Scambia G.
PMID: 27995174
Gynecol Oncol Rep. 2016 Nov 10;18:53-54. doi: 10.1016/j.gore.2016.11.003. eCollection 2016 Nov.

No abstract available.

Cite
Fagotti A, Vizzielli G, Petrillo M, et al. RE: Pattern of and reason for postoperative residual disease in patients with advanced ovarian cancer following upfront radical debulking surgery. Gynecol Oncol Rep. 2016;18:53-54doi: 10.1016/j.gore.2016.11.003.
Fagotti, A., Vizzielli, G., Petrillo, M., & Scambia, G. (2016). RE: Pattern of and reason for postoperative residual disease in patients with advanced ovarian cancer following upfront radical debulking surgery. Gynecologic oncology reports, 1853-54. https://doi.org/10.1016/j.gore.2016.11.003
Fagotti, A, et al. "RE: Pattern of and reason for postoperative residual disease in patients with advanced ovarian cancer following upfront radical debulking surgery." Gynecologic oncology reports vol. 18 (2016): 53-54. doi: https://doi.org/10.1016/j.gore.2016.11.003
Fagotti A, Vizzielli G, Petrillo M, Scambia G. RE: Pattern of and reason for postoperative residual disease in patients with advanced ovarian cancer following upfront radical debulking surgery. Gynecol Oncol Rep. 2016 Nov 10;18:53-54. doi: 10.1016/j.gore.2016.11.003. eCollection 2016 Nov. PMID: 27995174; PMCID: PMC5154694.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 2396 entries